Novartis Korea Ltd. clinical trials
A country office of Novartis
The registry lists 2 studies whose lead sponsor is Novartis Korea Ltd.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 29, 2016.
- 2studies on the registry
- 0open to participants now
What it is testing
The drugs Novartis Korea Ltd.’s studies test, most studies first; none is open now — 1 drug with a page of their own. Each count opens the studies in search.
Studies, none open
- Ranibizumab2 in phase 30 open · 2
All 2 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
- Completed2100%
Over the years
- 108
- 09
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 1 started before 2008. 2026 so far in the lighter column.
Registry sponsor names on this page
- Novartis Korea Ltd.2 studies
Something wrong with this grouping? Tell us on the Novartis page.
Studies
Recruiting first, then most recently updated. Showing 2 of 2. All Novartis studies →
- Effect of Intravitreal Ranibizumab Injection With Retinal Vein Occlusion (RVO)CompletedNCT00942864Phase 3
Sponsor listed in the registry: Novartis Korea Ltd.
- Combination of Ranibizumab and Verteporfin Therapy in Neovascular Age-related Macular DegenerationCompletedNCT00967213Phase 3
Sponsor listed in the registry: Novartis Korea Ltd.